Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Pradaxa is used to prevent blood clots from forming due to certain irregular heart rhythm.
Glenmark Pharmaceuticals was granted tentative approval by the United States Food and Drug Administration (USFDA) for Dabigatran Etexilate capsules at the advantages of 75 mg, 110 mg, and 150 mg, the company said in a regulatory filing.
Quoting IQVIA sales statistics for the 12 month period ending August 2020, Glenmark stated Pradaxa capsules, 75, 110 mg and 150 mg, market achieved annual sales of approximately USD 550.9 million.
Shares of the company were trading 2.32 percent higher at Rs 528 per scrip on the BSE.
